LCG
EPZM

Lisanti Capital Growth’s Epizyme, Inc EPZM Stock Holding History

Lisanti Capital Growth’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,555
Closed -$453K – 115
2013
Q2 		$453K Buy
+12,555
New +$323K 0.22% 97

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Lisanti Capital Growth's EPZM Position: Q3 2013 in Review

Lisanti Capital Growth sold out of Epizyme, Inc (EPZM) in Q3 2013, closing a stake of 12,555 shares — an estimated $453K sold.

Lisanti Capital Growth first reported a position in EPZM in Q2 2013 and held it in 1 quarter. The position peaked at $453K in Q2 2013. 67 funds tracked by Wall St. Rank hold EPZM as of Q3 2013.

  • Lisanti Capital Growth reported no remaining Epizyme, Inc position as of Q3 2013 after selling out during the quarter.
  • Lisanti Capital Growth sold 12,555 Epizyme, Inc shares in Q3 2013, an estimated $453K.
  • Lisanti Capital Growth first reported a position in Epizyme, Inc in Q2 2013 and held it in 1 quarter.
  • Lisanti Capital Growth's Epizyme, Inc position peaked at $453K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2013.

Based on Lisanti Capital Growth's 13F filing for Q3 2013, filed 14 Nov 2013.